Compass Pathways Plc (CMPS)
NASDAQ:CMPS
Want to see CMPS full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.41Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.Company Guidance
Positive Phase III Results & Robust Clinical Dataset
COMP360 produced positive data from two pivotal Phase III trials (005 and 006) with the program enrolling over 1,000 patients across late-stage studies and over 800 participants from the two pivotal Phase III trials. Trials were blinded for an unprecedented 26 weeks for psychiatry, supporting claims of clinically meaningful, rapid onset and extended durability. Reported response metrics included ~25% clinically meaningful response from a single administration (005) and ~40% with the addition of a second fixed dose (006). Safety, preclinical toxicology and CMC data cited as comprehensive and supportive for NDA.
Rolling NDA Submission & Priority Review Voucher (CNPV)
COMPASS is aligned with the FDA on a rolling NDA submission and has begun submitting modules. The company was awarded a Commissioner's National Priority Voucher (CNPV), which management says could enable an ultra-accelerated review timeline (target ~1–2 months after final NDA submission) and is actively engaging with FDA/DEA to explore acceleration opportunities.
Commercial Readiness & Experienced Leadership
Company is ramping commercial organization rapidly: leadership hires include executives who have launched >50 products. The commercial team has already expanded (team has doubled in recent months) and is engaging sites and building field infrastructure in anticipation of launch readiness by year-end.
Reimbursement & State Rescheduling Progress
COMPASS secured psychedelic-specific CPT Category III codes designed to be billable by the hour for monitoring time, improving the reimbursement framework for multi-hour psychedelic treatments. Management reports nearly 90% of the U.S. population live in states that intend to reschedule COMP360 within ~30 days of federal rescheduling, meaning state-level access barriers are materially reduced if federal rescheduling follows approval. Buy-and-bill penetration for analogous treatments is estimated at ~35–45% and expected to increase over time.
Strong Financial Position
Successful financing and warrant exercises in Q1 bolstered the balance sheet; management states cash runway extends well beyond launch and into 2028, supporting commercialization activities.
PTSD Program & VA Engagement
COMPASS is advancing a late-stage PTSD program (single Phase III/registration-focused trial planned) and is actively supporting VA studies and engagement. PTSD addressable population cited as ~13 million U.S. adults and the company expects VA participation and rollout planning to be a priority.
Large Market Opportunity & Economic Rationale
Management cites ~4 million treatment-resistant depression (TRD) patients in the U.S. and positions COMP360 as a potential blockbuster. Spravato is noted as expected to reach $3B by 2027 but treated <2% of TRD patients as of 2025, indicating a large unmet access opportunity. TRD patients have substantially higher economic burden: ~62% more mental health care costs and ~41% higher work-related costs versus MDD patients.
Differentiated Clinical Profile and Tolerability
Management emphasizes COMP360's differentiated combination of rapid onset and durability not offered by current TRD options, and describes a generally safe and well-tolerated profile across trials — a commercial and clinical differentiator for both TRD and PTSD.
CMPS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CMPS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $9.37 | $10.96 | +16.97% |
Mar 24, 2026 | $5.34 | $5.22 | -2.25% |
Nov 04, 2025 | $5.95 | $6.63 | +11.43% |
Jul 31, 2025 | $3.94 | $4.35 | +10.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Compass Pathways Plc (CMPS) report earnings?
Compass Pathways Plc (CMPS) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Compass Pathways Plc (CMPS) earnings time?
Compass Pathways Plc (CMPS) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMPS EPS forecast?
CMPS EPS forecast for the fiscal quarter 2026 (Q2) is -0.4.